-
Product Insights
Relapsed Chronic Lymphocytic Leukemia (CLL) – Drugs In Development, 2023
Global Markets Direct’s, ‘Relapsed Chronic Lymphocytic Leukemia (CLL) - Drugs In Development, 2023’, provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Drugs In Development, 2023’, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Mediastinal B-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Primary Mediastinal B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Mediastinal B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Peripheral T-Cell Lymphomas (PTCL) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral T-Cell Lymphomas (PTCL) - Drugs In Development, 2023’, provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Marginal Zone B-cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Marginal Zone B-cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Marginal Zone B-cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Marginal Zone B-cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) - Drugs In Development, 2023’, provides an overview of the B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Sector Analysis
Middle East and Africa (MEA) Household Products Market Opportunities, Trends, Growth Analysis and Forecast to 2027
MEA Household Products Market Report Overview The MEA household products market size was estimated at $22.8 billion in 2022 and is set to record a value CAGR of more than 10% from 2022 to 2027. Textile washing products category was the highest revenue contributor in the MEA household products sector in 2022. MEA Household Products Market Outlook 2022-2027 ($ Billion) Buy the Full Report for MEA Household Products Market Forecasts Download a Free Sample Report The MEA Household Products market...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cd30 in Natural Killer Cell Lymphomas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CD30 in Natural Killer Cell Lymphomas Drug Details:Gene therapy is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brilacidin in Inflammatory Bowel Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brilacidin in Inflammatory Bowel Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brilacidin in Inflammatory Bowel Disease Drug Details: Brilacidin (PMX-30063) is under...
-
Product Insights
Inflammatory Disease Markers Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Inflammatory Disease Markers Pipeline Market Report Overview Inflammatory Disease Markers are antigens/antibodies that detect specific antigens/antibodies produced by bone, cartilage, or any other inflammatory disease activity. The Inflammatory Disease Markers pipeline market research report provides comprehensive information about the inflammatory disease markers pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials that are in progress. Key Segments ·       Anti-Cyclic Citrullinated Peptide Antibody (Anti-CCP) Analyzer Tests ·       C-Reactive Protein (CRP)...